Reported about 24 hours ago
Shares of Edgewise Therapeutics plummeted over 20% following the announcement of results from its Phase 2 trial for the drug EDG-7500, aimed at treating Hypertrophic Cardiomyopathy. Although the drug met its main objective, reported side effects, including serious cardiac events in some patients, raised considerable concerns among investors, leading to a surge in shares of competitor Cytokinetics.
Source: YAHOO